Novo Nordisk, Wegovy
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...
Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...
Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in ...
Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...
In a society that has so many people who are overweight, it is understandable there’s such a craze for new drugs that are ...
People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...
Ozempic, Wegovy, Zepbound, and Mounjaro are but a few of the injectable drugs that are currently revolutionizing the size of ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback